Gene expression predictors in breast cancer: current status, limitations and perspectives

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Breast cancer exhibits significant heterogeneity in patient prognosis and response to therapies.
• Accurate prediction of individual patient outcomes and drug sensitivity is crucial for optimizing treatment strategies.
• Current molecular predictors, while valuable, are considered suboptimal in fully leveraging technological potential.

Purpose of the Study:

• To highlight the limitations of existing breast cancer molecular predictors.
• To advocate for the development of next-generation gene signatures for improved predictive accuracy.
• To enhance patient management through more precise prognostic and predictive tools.

Main Methods:

• Review of existing molecular predictor technologies (DNA-based arrays, RT-PCR).
• Analysis of current phase III trial data for established predictors (e.g., MammaPrint, Oncotype DX, DLD30, SET index).
• Discussion on the potential of novel study designs and advanced array technologies.

Main Results:

• Existing molecular predictors demonstrate good performance but are not fully optimized.
• There is a recognized need for more powerful predictive tools beyond current capabilities.
• Advanced genomic technologies offer potential for superior biomarker discovery.

Conclusions:

• Next-generation gene signatures are needed to overcome limitations of current breast cancer predictors.
• Improved prediction of prognosis and drug sensitivity will enhance patient care, quality of life, and survival.
• Future research should focus on innovative study designs and array technologies for developing superior biomarkers.